Democrat activist analysis of party leaders

11 December 2006

A prominent figure in the US Democratic party's on-line activist caucus, David Sirota, has compiled an analysis of his party's leadership, identifying potentially "drug industry-friendly" names. In an on-line article titled: People Party versus Money Party: Who's Who Among the Democrats, Mr Sirota, who was a leading figure in the Neil Lamont campaign to unseat Senator Joe Lieberman (Connecticut), describes the "People vs Money divide that actually fuels our politics."

Among the US Senators identified as opponents of business-friendly policies, Mr Sirota notes Sen Byron Dorgan (Democrat, North Dakota), who "has been one of the strongest voices against profiteering by the energy and pharmaceutical companies." Sen Dorgan is also described as opposed to "every major lobbyist-written trade deal that has come through the Senate," a reference to the free trade agreements between the USA and foreign nations, which complement the World Trade Agreement and often include provisions for the protection of drug industry intellectual property rights.

On the opposite side of the Democratic party, according to Mr Sirota, House of Representatives member Ellen Tauscher (California) is described as having promised that the party "would be engaging in a 'kabuki' dance" with Democratic base voters, a reference to a showy, theatrical Japanese dance form. This would fit in with some analysts who believe that the absence of a clear majority in the Senate and the perceived success of the Medicare Part D prescription drug benefit will reduce the Democrats to holding showcase hearings as an alternative to major reform (Marketletter December 4).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight